| Field | Specification |
|---|---|
| Target | |
| Alternative names | B-cell lymphoma/leukemia 10;B-cell CLL/lymphoma 10;Bcl-10;CARD-containing molecule enhancing NF-kappa-B;CARD-like apoptotic protein;hCLAP;CED-3/ICH-1 prodomain homologous E10-like regulator;CIPER;Cellular homolog of vCARMEN;cCARMEN;Cellular-E10;c-E10;Mammalian CARD-containing adapter molecule E10;mE10;BCL10;CIPER, CLAP; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human Bcl10 recombinant protein (Position: M1-Q233). Human Bcl10 shares 91% and 91.4% amino acid (aa) sequence identity with mouse and rat Bcl10, respectively. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes B-cell lymphoma/leukemia 10 (gene BCL10) in human samples and is validated for IHC and Western blot. The predicted molecular weight is 26.3 kDa, and the supplier reports an observed band at about 28 kDa.
BCL10 is an adaptor protein that assembles with CARD11 (CARMA1) and MALT1 to form the CBM complex after antigen receptor engagement in lymphocytes. This complex activates NF-κB and is essential for lymphocyte activation, and related CARD-containing partners use BCL10 in innate immune signaling. BCL10 alterations occur in some MALT lymphomas.
| Target | B-cell lymphoma/leukemia 10 (gene BCL10; UniProt O95999, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 26.3 kDa |
| Observed MW | 28 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
Samples with a confirmed band (WB): human Raji cells, human Jurkat cells, human MCF-7 cells, human HeLa cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human lymph node carcinoma tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Recombinant human Bcl10 fragment (Met1–Gln233), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 91% and 91.4%, respectively.
Reactivity Notes
The supplier lists reactivity with human. UniProt places B-cell lymphoma/leukemia 10 in the cytoplasm and membrane raft. Tissue expression noted by UniProt (human): Ubiquitous. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
